Jefferies Financial Group started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) in a research report sent to investors on Friday, MarketBeat reports. The firm issued a buy rating and a $40.00 price objective on the stock.
Separately, Wedbush initiated coverage on shares of Oruka Therapeutics in a research note on Wednesday, September 4th. They issued an outperform rating and a $40.00 price target on the stock.
View Our Latest Stock Report on ORKA
Oruka Therapeutics Price Performance
About Oruka Therapeutics
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
See Also
- Five stocks we like better than Oruka Therapeutics
- 10 Best Airline Stocks to Buy
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Best Stocks Under $5.00
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Short Selling: How to Short a Stock
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
